Radius Health
News/ News/ News/ Oncology/ R&D
End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial
Phil Taylor
amcenestrant, AstraZeneca, breast cancer, camizestrant, elacestrant, Eli Lilly, giridestrant, imlunestrant, Menarini Group, Oncology, Radius Health, Roche, Sanofi, serd
0 Comment
News/ News/ News/ Oncology/ R&D
Roche’s oral SERD giredestrant fails breast cancer trial
Phil Taylor
amcenestrant, breast cancer, elacestrant, Giredestrant, Menarini Group, Oncology, Radius Health, Roche, Sanofi, serd
0 Comment
Pfizer puts up $1bn to buy into Arvinas breast cancer programme
Phil Taylor
Arvinas, AstraZeneca, breast cancer, Oncology, Pfizer, protein degradation, Radius Health, Sanofi
0 Comment
Amgen/UCB reveal new osteoporosis drug data
Richard Staines
Amgen, osteoporosis, Radius Health, UCB
0 Comment
But romosozumab missed secondary endpoint of non-vertebral fractures